JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Начало・Списък с акции・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Затворен

СекторЗдравеопазване

24.75 0.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.66

Максимум

24.81

Ключови измерители
By Trading Economics
Приходи	51M -129M
Продажби	207M
Марж на печалбата	-62.319
Служители	1,371
EBITDA	8.8M -105M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+111.71% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	379M 2.4B
Предишно отваряне	24.43
Предишно затваряне	24.75

Настроения в новините

By Acuity

19%

81%

35 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

32.76 / 39.24 Подкрепа & съпротива

Ultragenyx Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.05.2026 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1.05.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1.05.2026 г., 18:37 ч. UTC

Значими двигатели на пазара

Senseonic Shares Slide on Underwritten Offering Price

1.05.2026 г., 16:46 ч. UTC

Значими двигатели на пазара

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2.05.2026 г., 19:57 ч. UTC

Придобивния, сливания и поглъщания

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2.05.2026 г., 15:24 ч. UTC

Печалби

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2.05.2026 г., 12:46 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.05.2026 г., 20:42 ч. UTC

Печалби

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1.05.2026 г., 19:18 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1.05.2026 г., 19:13 ч. UTC

Пазарно говорене

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1.05.2026 г., 18:36 ч. UTC

Печалби

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1.05.2026 г., 18:35 ч. UTC

Печалби

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1.05.2026 г., 18:28 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1.05.2026 г., 18:27 ч. UTC

Пазарно говорене

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1.05.2026 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Barclays Completes Acquisition of Best Egg

1.05.2026 г., 18:04 ч. UTC

Печалби

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1.05.2026 г., 17:43 ч. UTC

Пазарно говорене

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1.05.2026 г., 17:37 ч. UTC

Пазарно говорене

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1.05.2026 г., 17:30 ч. UTC

Пазарно говорене

Печалби

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1.05.2026 г., 17:28 ч. UTC

Пазарно говорене

Печалби

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1.05.2026 г., 17:21 ч. UTC

Пазарно говорене

Печалби

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1.05.2026 г., 17:19 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1.05.2026 г., 16:38 ч. UTC

Пазарно говорене

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1.05.2026 г., 16:23 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ultragenyx Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

111.71% нагоре

12-месечна прогноза

Среден 52.44 USD 111.71%

Висок 84 USD

Нисък 25 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Ultragenyx Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

Купи

Задържане

Продай

Според 18 анализатори, дали борсови рейтинги на Ultragenyx Pharmaceutical Inc през последните 3 месеца.

Техническа оценка

By Trading Central

32.76 / 39.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

35 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.